This Article
Right arrow Full Text (PDF)
Right arrow Letters to the Editor: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowReprints and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chrisman, O.
Right arrow Articles by Short, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Chrisman, O.
Right arrow Articles by Short, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Technorati  
What's this?

The Journal of Bone and Joint Surgery, Vol 58, Issue 7 918-920, Copyright © 1976 by Journal of Bone and Joint Surgery, Inc

JOURNAL CONTENTS

Prevention of venous thromboembolism by administration of hydroxychloroquine. A preliminary report

OD Chrisman, GA Snook, TC Wilson and JY Short

A placebo or the antimalarial agent hydroxychloroquine (Plaquenil), which inhibits platelet adhesiveness, and, to a lesser extent, platelet aggregation, was given to 100 patients between forty and ninety-five years old (average age, seventy-four years) who had either fractures or orthopaedic operations involving the skeleton between the knee and the pelvis. Medication was started at the time of admission in a blind, randomized way, fifty patients receiving hydroxychloroquine (200 milligrams three times a day) and fifty, a placebo. No untoward bleeding complications were noted in the treated group. Eight instances of thromboembolism were encountered in the control group as compared with one in the hydroxychloroquine-treated group, a statistically significant difference at the 1.5 per cent level.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 LupusHome page
M Fernandez, G McGwin Jr., A M Bertoli, J Calvo-Alen, L M Vila, J D Reveille, G S Alarcon, and for the LUMINA Study Group
Discontinuation rate and factors predictive of the use of hydroxychloroquine in LUMINA, a multiethnic US cohort (LUMINA XL)
Lupus, October 1, 2006; 15(10): 700 - 704.
[PDF]

Home page
 JBJSHome page
A. SARMIENTO and A. D. K. GOSWAMI
Thromboembolic Prophylaxis with Use of Aspirin, Exercise, and Graded Elastic Stockings or Intermittent Compression Devices in Patients Managed with Total Hip Arthroplasty
J. Bone Joint Surg. Am., March 1, 1999; 81(3): 339 - 46.
[Abstract] [Full Text]

Home page
 BMJHome page
A T Cohen, J A Skinner, and V V Kakkar
Antiplatelet treatment for thromboprophylaxis: a step forward or backwards?
BMJ, November 5, 1994; 309(6963): 1213 - 1215.
[Full Text]

Home page
 BMJHome page
R Collins, C Baignent, P Sandercock, and R Peto
Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials
BMJ, November 5, 1994; 309(6963): 1215 - 1217.
[Full Text]